5 AI-Powered Companies Transforming the Future of Fertility Care
The field of fertility treatments is experiencing a surge in demand, fueled by several significant factors. A shift towards starting families at a later age, the increasing number of same-sex couples seeking assistance, and concerning studies revealing a decline in male fertility are all contributing to this trend. According to the World Health Organisation (WHO), about 17.5% of adults worldwide—approximately 1 in 6—experience infertility, underscoring the need to expand access to affordable and reliable fertility care. The estimates show infertility affects people at similar rates across income levels, with lifetime prevalence at 17.8% in high-income countries and 16.5% in low- and middle-income countries, establishing infertility as a global health challenge.
#advertisement
The CDC’s latest National Health Statistics Report shows that infertility among married women in the United States rose from 6.7% in 2011–2015 to 8.7% in 2015–2019, meaning nearly one in ten women of reproductive age now face infertility.
Studies link infertility to significant psychological, financial, and relationship strain, with evidence showing reduced quality of life for many affected couples. Research has found infertility to be a leading factor in divorce, while depression rates are higher among infertile women than in the general population. Men with male factor infertility report more symptoms of depression, anxiety, and lower self-esteem. Additionally, women who conceive through IVF face more than twice the risk of premature birth.
Presently, available treatment options often come with a hefty price tag. In the United States, a single cycle of in vitro fertilization (IVF) can cost as much as $30,000. It's important to note that many patients typically require multiple cycles in order to achieve a successful pregnancy. The data collected by FertilityIQ shows, the average patient in the US will undergo 2.3-2.7x IVF cycles in total, so the spendings will be close to $50,000 in treatment.
Although IVF has been a widely used technique for over four decades, its outcomes remain unpredictable. Furthermore, access to fertility care remains dishearteningly low. In developed markets such as the United States, from women ages 15–49, about 1.7% reported ever having used artificial insemination and 0.5% reported using assisted reproductive technology such as vitro fertilization (IVF), according to CDC’s National Survey of Family Growth 2017–2019. IVF remains one of the least commonly used fertility services compared to advice, testing, or ovulation drugs.
In his comment to Forbes, Eran Eshed, the CEO of Fairtility, highlights the stagnation of data and artificial intelligence (AI) usage in influencing IVF outcomes, despite numerous advancements in biotechnology. Eshed emphasizes that while data science cannot resolve biological challenges, AI has the potential to revolutionize the IVF process by enhancing decision-making at every critical juncture.
In 2020, a Mexican fertility specialist Alejandro Chávez-Badiola, co-founder of the start-up Conceivable Life Sciences and one of the first physicians to apply AI in reproductive medicine, and his group published research showing that computer vision algorithms could predict genetically healthy embryos with 11.6% greater accuracy than doctors, followed by a study on miscarriage risk. The team later applied AI to sperm selection, adapting motion-tracking methods from sports analytics; the system identified a previously unknown corkscrew-like movement linked to healthy sperm and outperformed embryologists, boosting the rate of embryos developing to implantation readiness by 12%.
U.S. clinic data show that the use of in vitro fertilization (IVF) continues to grow, with the Society for Assisted Reproductive Technology reporting more than 95,000 babies born through assisted reproductive technology in 2023, which accounted for 2.6% of all births in the United States in 2023, up from around 60,000–70,000 annually a decade earlier. Now, let's delve into the realm of fertility technology and explore five companies that are advancing the integration of next generation tools, alongside AI & robotics, to revolutionize the field.
Conceivable Life Sciences
Conceivable Life Sciences was co-founded in 2022 by Mexican fertility doctor trained as an OBGYN and reproductive endocrinologist Alejandro Chávez-Badiola, together with entrepreneurs Alan Murray and Joshua Abram, who previously launched the FDA-approved robotic cryostorage start-up TMRW Life Sciences.
The idea emerged during the pandemic, when the group began exploring how to merge Chávez-Badiola’s AI-driven embryo and sperm evaluation software with TMRW’s hardware expertise. Conceivable has raised $70 million to date, including a $50 million Series A in September 2025 led by ARTIS Ventures, Stride, and ACME Ventures, to develop its AI-driven robotic IVF system designed to replicate the 205 manual steps from egg retrieval to embryo transfer.
The company adapted high-precision robotic arms, originally used in the semiconductor industry, to handle delicate biological material with micron-level accuracy. In trials at a clinic in Mexico City, Conceivable’s system, AURA, orchestrates 200+ steps of IVF, from dish preparation and sperm prep to egg finding, ICSI (including sperm selection/immobilization/loading/injection), incubation, vitrification/thawing, and transport between stations by a robotic “handler.” The process, which resembles an assembly line, is directed by algorithms that mimic the subtle techniques of embryologists, such as the pipette “shake” used during ICSI.
After proving the approach in mice, producing three generations of healthy pregnancies, Conceivable began human clinical trials in 2023, aiming to bring fully automated, AI-guided IVF closer to clinical adoption. Conceivable’s current human trial in Mexico City enrolls 125 women to test whether IVF can be performed with minimal human intervention using the AURA system.
Fairtility
Fairtility is a leading innovator in transparent AI for in vitro fertilization based in Israel. Fairtility addresses the need for objective and consistent data consolidation and interpretation in the embryology lab, which can significantly impact the success of IVF outcomes.
Their solution, CHLOE EQ (Cultivating Human Life through Optimal Embryos), is an AI-powered embryo quality assessment assistant designed to digitize and standardize the IVF lab workflow. The system analyzes millions of data points from patient and embryo records to assess developmental potential, reporting 96% accuracy for blastocyst prediction and 73% for implantation prediction. It automates embryo stage annotation, connects directly with electronic medical records (EMR) to cut administrative workload, and reduces human error by eliminating manual data entry. CHLOE EQ also provides secure remote access for clinicians, offering transparent, interpretable assessments to support embryo selection and improve IVF efficiency.
Fairtility expands its AI suite beyond CHLOE EQ with tools aimed at different stages of IVF care. CHLOE OQ applies image-based AI to evaluate the potential of individual oocytes, helping with fertility preservation decisions and identifying quality issues that could affect IVF success. CHLOE KPI monitors laboratory operations in real time, generating key performance indicators to detect problems early and prevent costly deviations. CHLOE DR translates complex lab data into accessible visuals, allowing physicians to provide personalized, transparent updates throughout the IVF process while reducing the need for manual reporting.
In May 2022 the company successfully raised $15 million in a Series A funding round, bringing the total funding to $18.5 million. The funding was led by Gurnet Point Capital, with participation from Nacre Capital and other investors. Fairtility plans to invest the Series A funding in clinical research collaborations with fertility clinics and academic institutions, as well as in regulatory approvals, while expanding CHLOE to cover the entire IVF journey. Their vision is to revolutionize IVF outcomes and accessibility through digitization and user-centric transparency.
In September 2025, Fairtility received FDA clearance for CHLOE Blast, part of its CHLOE AI platform for embryo assessment, making it the first FDA-cleared machine learning–based clinical decision support software in IVF. The tool analyzes time-lapse embryo images to provide objective and consistent evaluations, reducing reliance on manual judgment and supporting more transparent communication between clinicians and patients. The platform is reportedly already used with patients in Europe, Canada, and Asia Pacific.
Overture Life
Overture Life develops automation for assisted reproductive technology (ART) to help clinics scale capacity, lower costs, and deliver reproducible outcomes. Its systems target complex steps, including enabling standardized procedures that can be deployed at satellite sites so treatment moves closer to patients, and support fertility preservation workflows in high-demand urban centers.
Overture’s push to solve “fertility deserts” has shifted from lab-only robotics to portable automation: its palm-size DaVitri unit standardizes egg vitrification in ~15 minutes at satellite clinics and OB-GYN offices, with reported thaw-survival of 98.3% vs 96.4% for manual methods and an alleged 12% increase in blastocyst yield. The device has ANVISA clearance in Brazil and is being deployed across Latin America (including Panama, Chile, Dominican Republic, Argentina, and Peru), positioning vitrification closer to patients and reducing reliance on centralized embryology labs.
In July 2025, Overture signed a commercial agreement with Memorial Hospital Istanbul to run its ICSI.A robotic platform at one of Europe’s highest-volume IVF centers (targeting >6,000 cycles/year), while advancing clinical studies of DaVitri. The company reports $57M total funding and a CLIA-licensed U.S. lab supporting non-invasive embryo selection as it works toward broader regulatory clearances.
Overture plans to begin selling its DaVitri egg-freezing units across the European Union. The company is also seeking FDA clearance for DaVitri in the United States, where regulatory delays have slowed review timelines. While pricing has not been disclosed, CEO Hans Gangeskar stated that the devices cost Overture under $1,000 to manufacture, emphasizing that the company’s primary goal is to make IVF more affordable through scalable automation.
Alife
Founded in 2020 by CEO Paxton Maeder-York, who brings expertise in surgical robotics, Alife aims to modernize fertility treatments by leveraging AI and data science. The company has developed an AI-powered platform designed to streamline in vitro fertilization (IVF) workflows by integrating clinical and laboratory data into decision-making. Its suite includes Embryo Assist, which automates embryo image reporting and standardizes lab processes to reduce manual workload; Schedule Predict, which forecasts retrieval schedules up to a week in advance to reduce capacity bottlenecks and staff burnout; and Success Predictor, which provides automated patient counseling tools to support providers and improve patient engagement.
The system connects directly to electronic medical records (EMRs) without requiring new hardware, operates on a secure cloud infrastructure, and is SOC2 and HIPAA compliant. Alife emphasizes interpretability—ensuring clinicians can understand the basis of the model’s predictions.
The company has partnered with top fertility clinics to collect data and test their technology, with plans to expand its presence in the U.S. market and develop additional software features. In March 2022, the company secured $22 million in series A funding to support its objective of introducing its fertility products to the market and conducting clinical studies for its ongoing product development initiatives.
In May 2023, Alife Health unveiled its mobile application designed to assist patients throughout their IVF journey. The Alife app, available free of charge for iPhone users, offers a user-friendly interface that facilitates tracking test results, setting reminders for appointments and medications, accessing educational information, and preparing for the next steps in the process. With the Alife app, patients can easily monitor their progress, record symptoms and notes, compare cycles, and stay organized.
In 2024, Alife Health entered a partnership with Ovation Fertility, a U.S. laboratory network, to pilot its Embryo Assist software. The collaboration focuses on automating embryo image capture and digital cataloguing to streamline lab operations and reduce manual data handling. By creating structured digital records and providing an audit trail for each embryo, the system is designed to improve efficiency and quality control while laying the groundwork for future AI-assisted embryo selection. Alife expects that pairing Embryo Assist with its decision support algorithms could eventually support more consistent and precise identification of embryos for transfer.
AIVF
Another Israel-based fertility company, AIVF, specializes in AI-enabled solutions for in vitro fertilization (IVF) clinics. AiVF's EMA utilizes a powerful combination of artificial intelligence, computer vision, and extensive data sets to enhance the success rates of IVF treatments for patients. The evaluation tool offered by EMA aids in determining the genetic suitability of embryos for transfer. In 2021, EMA received approval from the CE certifying body, allowing it to be marketed and utilized in IVF fertility clinics throughout Europe.
EMA’s deep learning models analyze embryo morphology, morphokinetics, and ploidy probability, offering early-stage predictions at Day 3 and blastocyst assessments at Day 5 to guide embryo transfer decisions. Additional modules include AIVF Genetics, a non-invasive tool for assessing embryo genetic integrity, and specialized algorithms such as a Resilience Model to account for medical interventions, a Morphokinetics Model for tracking developmental milestones, and a Segmentation Model for precise embryo imaging. Integrated with EMR systems and incubators, EMA also provides advanced IVF analytics and real-time messaging to streamline workflows, reduce manual tasks, and support data-driven clinical decisions.
AIVF raised $25 million in a Series A funding round in October 2022 led by Insight Partners, which will be utilized to expedite the adoption of their EMA platform in the U.S. and Europe, expand their team, and develop new fertility tools. Part of this funding has been used to acquire lab management software company ART Compass.
In May 2023 AIVF partnered with Genea Biomedx, a provider of medical devices for IVF laboratories. Genea Biomedx offers the Geri time-lapse incubator, a benchtop incubator with individual chambers for storing embryos, equipped with cameras to monitor their development. Through this collaboration, AIVF's EMA platform will be integrated into the Geri incubator, combining imaging capabilities with AI-enabled analytics to enhance the success rate of IVF treatments and provide patients with access to valuable embryo data.
In September 2023, AIVF launched its EMA AI-powered IVF operating system at the Perfetto Clinic in Goiânia, Brazil, marking the company’s first deployment in Latin America. The expansion comes as Brazil’s IVF market has grown rapidly—registered clinics rose by 63% and frozen embryos tripled between 2013 and 2019, according to the release—positioning EMA as a data-driven platform to support the region’s rising demand for fertility care.
Cover image credit: Artwork created by Adolfo Flores Saiffe on the Mexico City team shows embryos from the clinic’s patients at different stages of development, mocked up by AI. Visual aspects of the embryo are highlighted by computer vision filters the team built to detect the health of the embryo. (Conceivable Life Sciences)
Article updated by Rohozianska Anastasiia
Topic: AI in Bio
